LiquidLung

A simple blood test to support earlier lung cancer detection.

LiquidLung is developing LiquidLung-EDT™ — an RNA-powered blood test designed to help identify lung cancer earlier in high-risk individuals, before symptoms appear, when treatment options may be more effective.

Earlier signal. Clearer triage. Better screening participation.

02The Problem

Lung cancer is still being found too late.

Lung cancer remains the leading cause of cancer death in the United States. The tragedy is not only that lung cancer is deadly, it is that too many cases are discovered after the window for earlier intervention has already narrowed.

When lung cancer is found while still localized, 5-year relative survival is dramatically higher than when it is found after distant spread. But today, the majority of lung cancers are diagnosed at advanced stages.

Three-dimensional translucent lungs with a tumor in the airway
Statistic 1
51%of lung and bronchus cancers are diagnosed after distant spread.
Statistic 2
65.5% vs. 10.5%5-year relative survival for localized vs. distant lung and bronchus cancer.
Statistic 3
81.8%of eligible high-risk individuals did not receive lung cancer screening.

03Why Current Screening Falls Short

LDCT can detect lung cancer. But participation remains too low.

Annual low-dose CT screening is recommended for high-risk adults. But real-world participation remains limited by awareness, access, scheduling friction, patient anxiety, workflow burden, and other practical barriers.

For many patients, getting to an imaging appointment is not simple. It can mean time away from work, transportation challenges, anxiety about the scan, and uncertainty about whether they truly need it.

LiquidLung-EDT™ is being developed to meet patients earlier in the pathway, through a blood draw that can help identify who may need imaging next.

Laboratory blood sample tube and pipette in cool light

04The Solution

Introducing a blood-first approach to targeted lung cancer screening.

Meet LiquidLung-EDT™ — an RNA-based blood test in development to help guide high-risk individuals toward appropriate lung cancer screening.

  1. 01

    High-risk patient identified

    Eligible by age, smoking history, or other risk factors.

  2. 02

    Blood test ordered

    Simple blood draw during routine care or screening outreach.

  3. 03

    Molecular signal assessed

    RNA-based signature evaluates lung cancer-associated biology.

  4. 04

    Biologic signal guides next steps.

    Positive results may support imaging escalation.

Illustrative proposed workflow. LiquidLung remains investigational and is not available for clinical use.

05Positioning Statement

Not a replacement for imaging. A smarter front door to imaging.

LDCT remains an important tool in lung cancer screening.

LiquidLung-EDT™ is being developed as a targeted molecular triage tool, a simple blood test designed to help bring the right patients into imaging at the right time.

06The Science

Why RNA matters for early lung cancer detection.

Many blood-based cancer detection approaches focus on tumor-derived DNA. But early tumors may shed very little DNA, making the earliest-stage disease difficult to detect.

LiquidLung-EDT™ focuses on cell-free RNA, which can reflect active biological processes in real time.

Our patented dual-source cfRNA approach is designed to capture two complementary sources of signal:

Blood sample

Dual-source cfRNA

When integrated, these dual sources of active RNA expression yield a stronger signal in early-stage disease than tumor material alone.

07Why LiquidLung Is Different

Active biology, not just tumor shedding.

LiquidLung-EDT™ is designed around the idea that early lung cancer may create detectable biological changes before tumor burden is large enough to reliably capture through tumor-derived DNA.

By measuring RNA signals associated with both the body’s response and lung/tumor context, LiquidLung-EDT™is being developed to detect early-stage disease biology in blood.

01

Biologic signal

Dual-source cfRNA captures active disease biology.

02

Clinical fit

A blood-first approach designed to support LDCT triage.

03

Scalable technology

Designed for clinical laboratory workflows and broad screening use.

08Evidence & Readiness

Built on a foundation of published evidence.

Our technology has been validated in more than 5,000 patients.

The ASCO study: an example of large independent external validation.

LiquidLung’s published ASCO work evaluated a machine-learning approach using RNA gene expression in a large, predominantly early-stage lung cancer cohort.

In a 3,744-subject cohort, the LiquidLung-EDT™ signature achieved 98% sensitivity and 89% specificity in a held-out test set.

The cohort was heavily weighted toward early-stage lung cancer, with broad representation across histologic types.

3,744-subject cohort

Prevalent lung cancer types/subtypes and non-cancer controls.

98% sensitivity / 89% specificity

Performance in the held-out test set.

Predominantly early-stage

The lung cancer cohort was heavily weighted toward Stage I/II disease.

These figures are results from the described research cohort. They are not established real-world screening performance. LiquidLung remains investigational, is not FDA-approved or commercially available, and has not been clinically validated for screening.

09Our Origins

Born from the IVBH studio.

Built for lung health.

LiquidLung is a focused lung health franchise created within IVBH, a creative-technical studio built to discover hidden biological meaning and translate it into real-world products.

IVBH starts with a belief that disease rarely reveals itself through a single obvious signal. Long before disease becomes clinically apparent, subtle changes are already occurring across biology. By searching the relationships among those signals, IVBH works to discover biological signatures that can become the source material for earlier detection.

LiquidLung was purpose-built to carry that work forward in lung health. Our first frontier is lung cancer, one of the clearest examples of a disease where knowing sooner can change everything.

10Partner With LiquidLung

Help build the next front door to lung cancer screening.

LiquidLung is seeking clinical, laboratory, diagnostic, imaging, strategic, and commercial partners interested in advancing blood-based lung cancer screening and triage.

Let’s collaborate.